{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T15:36:02Z","timestamp":1648913762799},"reference-count":24,"publisher":"Georg Thieme Verlag KG","issue":"20","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1055\/a-1239-2792","type":"journal-article","created":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T22:31:01Z","timestamp":1634164261000},"page":"1344-1351","source":"Crossref","is-referenced-by-count":0,"title":["Endokrine Orbitopathie"],"prefix":"10.1055","volume":"146","author":[{"given":"Anja","family":"Eckstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"M\u00f6ller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dagmar","family":"F\u00fchrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Oeverhaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2021,10,13]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41572-020-0184-y","article-title":"Graves\u02bc disease","volume":"6","author":"T F Davies","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1530\/EJE-18-0039","article-title":"Predictive score for the development or progression of Graves\u02bc orbitopathy in patients with newly diagnosed Graves\u02bc hyperthyroidism","volume":"178","author":"W Wiersinga","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"S 05","key":"ref3","first-page":"45","article-title":"[Morbidity after subtotal and total thyroidectomy in patients with Graves\u02bc disease: the basis for decision-making regarding surgical indication and extent of resection]","volume":"98","author":"H Dralle","year":"2004","journal-title":"Z\u00a0Arztl Fortbild Qualitatssich"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1136\/bjo.2007.137265","article-title":"Euthyroid and primarily hypothyroid patients develop milder and significantly more asymmetrical Graves ophthalmopathy","volume":"93","author":"A K Eckstein","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1001\/archinte.1990.00390170124027","article-title":"Effect of abnormal thyroid function on the severity of Graves\u02bc ophthalmopathy","volume":"150","author":"M F Prummel","year":"1990","journal-title":"Arch Intern Med"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1365-2265.1997.2331047.x","article-title":"Clinical activity score as a guide in the management of patients with Graves\u02bc ophthalmopathy","volume":"47","author":"M P Mourits","year":"1997","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1530\/EJE-07-0666","article-title":"Consensus statement of the European Group on Graves\u02bc orbitopathy (EUGOGO) on management of GO","volume":"158","author":"L Bartalena","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000443828","article-title":"The 2016 European Thyroid Association\/European Group on Graves\u02bc Orbitopathy Guidelines for the Management of Graves\u02bc Orbitopathy","volume":"5","author":"L Bartalena","year":"2016","journal-title":"Eur Thyroid J"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"3464","DOI":"10.1210\/jc.2005-2813","article-title":"Thyrotropin receptor autoantibodies are independent risk factors for Graves\u02bc ophthalmopathy and help to predict severity and outcome of the disease","volume":"91","author":"A K Eckstein","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"5234","DOI":"10.1210\/jc.2005-0148","article-title":"Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves\u02bc orbitopathy","volume":"90","author":"G J Kahaly","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"4454","DOI":"10.1210\/jc.2012-2389","article-title":"Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves\u02bc orbitopathy","volume":"97","author":"L Bartalena","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S2213-8587(18)30020-2","article-title":"Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves\u02bc orbitopathy (MINGO): a randomised, observer-masked, multicentre trial","volume":"6","author":"G J Kahaly","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/cen.13170","article-title":"Efficacy and safety of mycophenolate mofetil in patients with active moderate-to-severe Graves\u02bc orbitopathy","volume":"86","author":"X Ye","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1055\/s-0043-116945","article-title":"Combination Therapy of Intravenous Steroids and Orbital Irradiation is More Effective Than Intravenous Steroids Alone in Patients with Graves\u02bc Orbitopathy","volume":"49","author":"M Oeverhaus","year":"2017","journal-title":"Horm Metab Res"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ajo.2018.07.038","article-title":"Efficacy of Tocilizumab in Patients With Moderate-to-Severe Corticosteroid-Resistant Graves Orbitopathy: A Randomized Clinical Trial","volume":"195","author":"J V Perez-Moreiras","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1210\/jc.2014-3014","article-title":"Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe graves\u02bc orbitopathy: a randomized controlled study","volume":"100","author":"M Salvi","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S2213-8587(18)30021-4","article-title":"Combined immunosuppression and radiotherapy in thyroid eye disease (CIRTED): a multicentre, 2\u200a\u00d7\u200a2 factorial, double-blind, randomised controlled trial","volume":"6","author":"R Rajendram","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1365-2362.1986.tb01016.x","article-title":"Ciclosporin and prednisone v. prednisone in treatment of Graves\u02bc ophthalmopathy: a controlled, randomized and prospective study","volume":"16","author":"G Kahaly","year":"1986","journal-title":"Eur J Clin Invest"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1910434","article-title":"Teprotumumab for the Treatment of Active Thyroid Eye Disease","volume":"382","author":"R S Douglas","year":"2020","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","article-title":"Teprotumumab for Thyroid-Associated Ophthalmopathy","volume":"376","author":"T J Smith","year":"2017","journal-title":"N Engl J Med"},{"issue":"S 01","key":"ref21","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1159\/000511871","article-title":"Modulating TSH Receptor Signaling for Therapeutic Benefit","volume":"9","author":"G Krause","year":"2020","journal-title":"Eur Thyroid J"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-020-01361-y","article-title":"Dysthyroid optic neuropathy: evaluation and management","author":"P J Dolman","year":"2020","journal-title":"J Endocrinol Invest"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1055\/a-0959-0711","article-title":"Update Endokrine Orbitopathie","volume":"42","author":"A Eckstein","year":"2019","journal-title":"Der Nuklearmediziner"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.beem.2011.11.002","article-title":"Surgical treatment of Graves\u02bc ophthalmopathy","volume":"26","author":"A Eckstein","year":"2012","journal-title":"Best Pract Res Clin Endocrinol Metab"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1239-2792.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T22:32:10Z","timestamp":1634164330000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1239-2792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":24,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2021,10,13]]},"published-print":{"date-parts":[[2021,10]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1239-2792","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10]]}}}